Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Large B-cell Lymphoma, Small Lymphocytic Lymphoma
Conditions
Keywords
CAR-T, Ibrutinib, CLL, DLBCL, ALL, BLRM, YTB323, Rapcabtagene autoleucel
Brief summary
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Detailed description
This clinical trial is phase I/II open label, multi-center study of rapcabtagene autoleucel. The Phase I part of the study comprises three independent treatment arms: * Rapcabtagene autoleucel in combination with ibrutinib in adult CLL/SLL participants with SD or PR after at least 6 months of second or subsequent line ibrutinib therapy. As of 05-May-2021, this arm had completed enrollment. * Rapcabtagene autoleucel single agent in adult DLBCL participants having failed two or more lines of chemotherapy and either having progressed (or relapsed) after autologous HSCT or being ineligible for or not consenting to the procedure. * Rapcabtagene autoleucel single agent in adult relapsed/refractory ALL participants The Phase II part of the study comprises two independent cohorts: * Rapcabtagene autoleucel single agent in adult 3L + DLBCL participants having failed two or more lines of chemoimmunotherapy and either having progressed (or relapsed) after autologous HSCT or being ineligible for or not consenting to the procedure. This is an extension of the Phase I r/r DLBCL treatment arm to support Phase II objectives * Rapcabtagene autoleucel single agent in newly diagnosed, adult 1L HR LBCL participants defined as IPI 3-5 and/or DH/TH disease who have completed 2 cycles of CIT and have a response of PR/SD (with a Deauville score of 4-5). In the Phase I part of the trial, the 3L+ DLBCL and ALL arms consist of two parts: a dose escalation part to evaluate feasibility, characterize safety and identify the recommended dose (RD) of rapcabtagene autoleucel, and may be followed by a dose expansion part to further characterize safety, study rapcabtagene autoleucel cellular kinetics and assess preliminary antitumor activity. Once the RD of rapcabtagene autoleucel is determined for each arm, the corresponding expansion part may commence. In the Phase II part of the trial, approximately 70 additional participants will be enrolled in a 3L+ DLBCL cohort treated at the recommended dose (RD). Including the 3L+ DLBCL participants who were treated at the RD from the Phase I part, it is planned to have in total a cohort of approximately 100 participants included in the primary efficacy analysis based on the efficacy analysis set. In addition, a separate cohort in 1LHR LBCL will be included, with approximately 50-60 participants planned for the primary efficacy analysis based on the efficacy analysis set. Participants will be followed under the current treatment protocol for safety and efficacy within this trial for a minimum of 2 years before being transferred to the long-term follow-up trial. Once the study is complete, participants will be enrolled in a post-study long term follow-up for lentiviral vector safety for up to 15 years. This post-study long term follow-up for lentiviral vector safety will continue under a separate destination protocol.
Interventions
BIOLOGICALRapcabtagene autoleucel single agent
Single infusion of rapcabtagene autoleucel
DRUGIbrutinib
Tablets or capsules for oral daily use
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* ECOG performance status 0-1 for ALL and DLBCL * ECOG performance status 0-2 for 1L HR LBCL at screening * CLL or SLL diagnosis according to iwCLL criteria * CLL/SLL in SD or PR after at least 6 months of ibrutinib, either as second or subsequent line of therapy * DLBCL diagnosis by local histopathology * DLBCL relapsed or refractory after 2 or more lines of therapy, including autologous hematopoietic stem cell transplantation (HSCT) * Refractory or relapsed CD19-positive ALL * ALL with morphologic disease in the bone marrow 1L HR LBCL - Considered to be high-risk based on at least 1 of the following at diagnosis: * IPI score of 3, 4 or 5 * MYC and BCL2 and/or BCL6 rearrangement (DH/TH lymphoma) * Participants must have received 2 cycles of frontline therapy for LBCL with R-CHOP or Pola-R-CHP or DA-EPOCH-R. Participants with DH/TH lymphoma must have received at least one cycle (the most recent) DA-EPOCH-R. * Participants must have a positive PET per Lugano classification (Deauville PET score of 4 or 5 and an overall response of PR/SD) after 2 cycles of frontline CIT. Note: Patient's with Deauville PET score of 5 and overall response of PD, or with Deauville PET score of 1, 2, or 3 and overall response of CR, are not eligible for this trial.
Exclusion criteria
* Prior CD19-directed therapy * Prior administration of a genetically engineered cellular product * Prior allogeneic HSCT * Richter's transformation * For 1L HR LBCL: Richter's transformation, Burkitt lymphoma, primary DLBCL of CNS, DLBCL associated with chronic inflammation, intravascular large B-cell lymphoma, ALK- positive large B-cell lymphoma, HHV8 positive LBCL, DLBCL leg type or EBV positive DLBCL, NOS. * Active CNS lymphoma * For 1L HR LBCL: Active or prior history CNS involvement by malignancy * Targeted small molecule or kinase inhibitor within 2 weeks from leukapheresis Other protocol-defined inclusion/exclusion may apply.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1: Dose recommendation: Incidence and nature of Dose Limiting Toxicities (Dose Escalation part only) | 28 days | — |
| Phase 1: Safety: Incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signs | 24 months | — |
| Phase 1: Tolerability: Ibrutinib dose modifications in the CLL/SLL arm | 24 months | — |
| Phase 1: Manufacture success: Number of patients infused with planned target dose | 24 months | — |
| Phase 2: Complete Response Rate (CRR) as assessed by local Investigator | 24 months | CRR defined as best overall response (BOR) of CR after rapcabtagene autoleucel infusion as per Lugano criteria for 3L+ Diffuse Large B-Cell Lymphoma (DLBCL) and 1L High Risk Large B-Cell (HR LBCL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1: Complete Response (CR)/Partial Response (CR) in CLL/SLL | 24 months | per international workshop on Chronic Lymphocytic Leukemia (iwCLL) response criteria |
| Phase 1: BOR of CR/PR per Lugano criteria in 3L+ DLBCL | 24 months | — |
| Phase 1: Duration of response (DOR) in CLL/SLL and 3L+ DLBCL | 24 months | DOR as assessed by time from first achievement of CR/PR after rapcabtagene autoleucel infusion until first documented disease progression or death due to any cause |
| Phase 1: BOR in ALL as assessed by an Independent Review Committee (IRC) | month 3 | BOR of CR/CRi by 3 months after rapcabtagene autoleucel infusion as per IRC assessment. |
| Phase 1: DOR in ALL as assessed by an Independent Review Committee | 24 months | DOR, defined as the time from achievement of CR or CRi to relapse or death due to any cause |
| Phase 1: EFS in ALL as assessed by an Independent Review Committee | 24 months | EFS, defined as the date from rapcabtagene autoleucel infusion to the earliest date of relapse after CR/CRi, treatment failure (defined as failure to achieve CR/CRi within 12 weeks of infusion), or death due to any cause |
| Phase 1: BOR in ALL as assessed by local Investigator | 24 months | BOR of CR/CRi |
| Phase 1: DOR in ALL as assessed by local Investigator | 24 months | DOR, defined as the time from achievement of CR or CRi to relapse or death due to any cause. |
| Phase 1: EFS in ALL as assessed by local Investigator | 24 months | EFS, defined as the date from rapcabtagene autoleucel infusion to the earliest date of relapse after CR/CRi, treatment failure (defined as failure to achieve CR/CRi within 12 weeks of infusion), or death due to any cause |
| Phase 1: Overall survival in adult ALL | 24 months | OS defined as time from the date of infusion to the date of death due to any reason |
| Phase 1: MRD negative status by flow cytometry in adult ALL | 24 months | — |
| Phase 1: Quality of life in adult ALL patients enrolled in the expansion part by use of Electronic Patient Reported Outcomes (ePRO) as per EORTC QLQ-C30 questionnaire | 24 months | — |
| Phase 1: Quality of life in adult ALL patients enrolled in the expansion part by use of Electronic Patient Reported Outcomes (ePRO) as per EQ-5D-3 questionnaire | 24 months | — |
| Phase 1/2: Cellular kinetics | 24 months | CAR transgene levels by quantitative polymerase chain reaction (qPCR) in peripheral blood, bone marrow and lymph nodes |
| Phase 1/2: Immunogenicity | 24 months | Cellular and humoral responses to the CAR transgene |
| Phase 2: Overall response rate (ORR) | 24 months | ORR defined as BOR of CR/PR as per Lugano criteria in 3L+ DLBCL and 1L HR LBCL |
| Phase 2: Complete Response Rate (CRR) | months 3, 6 | CRR at months 3, 6 in 3L+ DLBCL |
| Phase 2: Duration of response (DOR) | 24 months | DOR defined as time from first CR/PR to first documented progression or death due to any cause in 3L+ DLBCL and 1L HR LBCL |
| Phase 2: Progression-free survival (PFS) | 24 months | PFS defined as time from rapcabtagene autoleucel infusion to first documented progression or death due to any cause in 3L+ DLBCL and 1L HR LBCL |
| Phase 2: Event-free survival (EFS) | 24 months | EFS defined as time from rapcabtagene autoleucel infusion to first documented progression, start of new anti-lymphoma therapy, biopsy-proven residual disease on or after month 6, or death due to any cause in 1L HR LBCL |
| Phase 2: Overall survival (OS) | 24 months | OS defined as time from date of rapcabtagene autoleucel infusion to date of death due to any cause in 3L+ DLBCL and 1L HR LBCL |
| Phase 2: Complete Response Rate (CRR) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH | months 6, 12 | CRR at months 6, 12 in 1L HR LBCL |
| Phase 2: Overall response rate (ORR) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH | 24 months | ORR defined as BOR of CR/PR as per Lugano criteria 1L HR LBCL |
| Phase 2: Duration of response (DOR) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH | 24 months | DOR defined as time from first CR/PR to first documented progression or death due to any cause in 1L HR LBCL |
| Phase 2: Progression-free survival (PFS) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH | 24 months | PFS defined as time from rapcabtagene autoleucel infusion to first documented progression or death due to any cause in 1L HR LBCL |
| Phase 2: Event-free survival (EFS) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH | 24 months | EFS defined as time from rapcabtagene autoleucel infusion to first documented progression, start of new anti-lymphoma therapy, biopsy-proven residual disease on or after month 6, or death due to any cause in 1L HR LBCL |
| Phase 2: Overall survival (OS) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH | 24 months | OS defined as time from date of rapcabtagene autoleucel infusion to date of death due to any cause in 1L HR LBCL |
| Phase 2: Manufacturing vein to door time | 24 months | Time from apheresis completion until return of rapcabtagene autoleucel product to the clinic or hospital |
Countries
Australia, Austria, France, Germany, Italy, Japan, Spain, United States
Contacts
STUDY_DIRECTORNovartis Pharmaceuticals
Novartis Pharmaceuticals
Outcome results
None listed